Literature DB >> 2991500

Rapid down regulation of beta adrenergic receptors by combining antidepressant drugs with forced swim: a model of antidepressant-induced neural adaptation.

G E Duncan, I A Paul, T K Harden, R A Mueller, W E Stumpf, G R Breese.   

Abstract

The hypothesis that behavioral responses to antidepressant drugs in the forced swim test are related to a rapid neural adaptation produced by the combination of drug treatment and swim stress was explored. As a measure of adaptation, brain beta adrenergic receptors were assayed using [3H]dihydroalprenolol [( 3H]DHA) binding to brain membranes from rats that were processed in the forced swim test. The combination of swim stress and imipramine treatment antagonized immobility induced by forced swimming and resulted in a reduction in [3H] DHA binding to membranes from forebrain preparations which did not include the corpus striatum. Administration of antidepressant drugs from other chemical classes, including pargyline, iprindole and nomifensine, also reduced immobility induced by the forced swim and produced a reduction in [3H]DHA binding to forebrain membranes. In homogenates of the corpus striatum, [3H]DHA binding was not altered by swim stress combined with antidepressant drug treatment. Chlordiazepoxide was without an effect on immobility or beta receptor binding when combined with forced swim. Even though atropine and amphetamine exhibited a positive activity in the forced swim test, they did not reduce [3H]DHA binding. Therefore, by combining behavioral and neurochemical analysis of animals processed in the forced swim test, it may be possible to differentiate, with greater confidence, potential antidepressant drugs from "false positives." The present studies support the hypothesis that antidepressant drug action in the forced swim test involves a rapid neural adaptation as reflected by the down regulation of beta adrenergic receptors. Thus, this behavioral paradigm may serve as a model of adaptive mechanisms induced by antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991500

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Noradrenergic and opioid mediation of tricyclic-induced reversal of escape deficits caused by inescapable shock pretreatment in rats.

Authors:  P Martin; P Soubrié; P Simon
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Effect of chronic administration of antidepressant drugs on 5-HT2-mediated behavior in the rat following noradrenergic or serotonergic denervation.

Authors:  A S Eison; F D Yocca; G Gianutsos
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone.

Authors:  G E Duncan; D J Knapp; S W Carson; G R Breese
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

4.  Acute versus repeated administration of desipramine in rats and mice: relationships between brain concentrations and reduction of immobility in the swimming test.

Authors:  M Poncelet; G Gaudel; S Danti; P Soubrié; P Simon
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Discovery of antidepressant activity by forced swimming test may depend on pre-exposure of rats to a stressful situation.

Authors:  F Borsini; A Lecci; A Sessarego; R Frassine; A Meli
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 6.  Is the forced swimming test a suitable model for revealing antidepressant activity?

Authors:  F Borsini; A Meli
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  The significance of beta-adrenoceptor down regulation in the desipramine action in the forced swimming test.

Authors:  Y Kitada; T Miyauchi; T Kosasa; S Satoh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-05       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.